A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

July 31, 2026

Conditions
Plaque Psoriasis
Interventions
DRUG

Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment

"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."

DRUG

placebo

"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."

All Listed Sponsors
lead

Beijing Hospital of Traditional Chinese Medicine

OTHER

NCT06396013 - A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome. | Biotech Hunter | Biotech Hunter